BlueRun Ventures Leads AllinkBio's $42 Million Series A Round | BlueRun Ventures

AllinkBio announced today that it has completed a $42 million Series A financing round. The round was led by BlueRun Ventures, with participation from YuanSheng Ventures, Legend Capital, and C&D Emerging Investment, alongside follow-on investments from existing shareholders Gaorong Ventures and Med-Fine Capital. AllinkBio is dedicated to developing next-generation bispecific antibody and ADC therapies to bring better treatment options to patients with cancer and immune diseases. The proceeds from this round will help accelerate AllinkBio's global expansion, including advancing its core pipeline candidates ALK201 and ALK202 through Phase I clinical trials in Australia, the United States, and China, while actively broadening its R&D pipeline in oncology and immunology, continuously optimizing its proprietary bispecific antibody and ADC technology platforms, and building a globally influential biotechnology company. "In just over a year since our founding, we have made a rapid leap from preclinical to clinical stages," said Dr. Hui Feng, Founder and CEO of AllinkBio. "Given the current financing environment for the biopharma industry, we are especially grateful for the continued trust and support of our existing shareholders, and honored to welcome new investment partners who recognize our innovation capabilities and execution efficiency. With their support, we will be able to advance our innovative pipeline more quickly, including next-generation ADCs and bispecific antibodies, bringing new therapeutic hope to patients with cancer and immune diseases. In the coming months, we expect to achieve multiple R&D milestones that will further propel our mission to develop innovative therapies for patients." BlueRun Ventures stated: "AllinkBio possesses proprietary bispecific antibody and ADC technology platforms, and we are very optimistic about its outstanding advantages in novel target discovery, bispecific antibody, and ADC new drug development. The company's pipeline layout is clear, particularly with two innovative molecules already in clinical stages that demonstrate significant breakthrough potential in oncology treatment. Dr. Hui Feng, as one of the leading figures in China's biopharma sector, has led the AllinkBio team with highly efficient execution in advancing the R&D pipeline, which further strengthens our confidence in the company's growth prospects." The completion of this financing round opens a new chapter for AllinkBio's development. Based on the company's highly efficient innovative drug R&D capabilities and the strategic vision of its leadership team in the biopharma field, the ample funding from this Series A round will help AllinkBio establish a leading position in the international competitive landscape of innovative drug development.

BlueRun Ventures in Conversation with Moonshot AI, Muyan Zhiyu: Standing at the Crossing of the AI Industry | The Road to AGI

BlueRun Ventures Family Headlines | Math rivaling the o1 series, search evolving once again — Kimi's new reasoning model expands the boundaries of intelligence with you

UniUni Completes $30 Million C2 Round | BlueRun Ventures Family